Crystal form of JAK inhibitor and preparation method thereof
AssigneeCrystal Pharmatech Co., Ltd.
InventorsMinhua Chen, Yanfeng Zhang, Xiaojuan Diao, Nan Xia, Xiaoyu Zhang
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to novel crystalline forms of JAK inhibitors and the preparation method thereof. The novel crystalline forms in the present disclosure can be used for the treatment of autoimmune diseases, particularly for the treatment of rheumatoid arthritis. The novel crystalline forms in the present disclosure have good stability and remarkable purification effect in process, moreover, its solubility and hygroscopicity meet the requirements for medical use. The preparation method of novel crystalline forms is simple, low cost, and has an important value for future optimization and development of the drug.
Claims1
A crystalline Form II of {1-(ethylsulfonyl))-3-[4-(7H-pyrrolo[2,3-d]pyrimidine-4-yl)-1H-pyrazol-1-yl]azetidine-3-yl}acetonitrile, wherein the X-ray powder diffraction pattern shows characteristic peaks at 2theta values of 18.00°±0.20°, 10.80°±0.20° and 7.26°±0.20°.
Dependencies are inferred from the claim text.